Floatz logo

Pelcitoclax

Relapsed/Refractory

M.D. Anderson Cancer CenterSmall moleculePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

15 Active assets in the Relapsed/Refractory cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
M.D. Anderson Cancer Center
Phase 2B
PAN-FGFR TYROSINE KINASE INHIBITOR JNJ-42756493
University Health Network, Toronto
Phase 2CCC
Bcma Car-T Cells
The First Affiliated Hospital of Xiamen University
Phase 2CCC
Cytosin-Arabinosid
M.D. Anderson Cancer Center
Phase 1/2CCC
Mezagitamab
Millennium Pharmaceuticals, Inc.
Phase 1/2CCC

View all 18 →

Same molecule, other indications

Pelcitoclax is also rated in:

small cell lung carcinomaDormant
CCC
Indicative ·
49 / 100
View asset →
non-Hodgkin lymphomaDormant
CCC
Indicative ·
48 / 100
View asset →
Phase IDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →